Microdosing GLP-1s Like Wegovy, Zepbound May Still Lead to Weight Loss
Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods. After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those…
Research indicates that microdosing certain GLP-1 medications, such as Wegovy and Zepbound, may still result in weight loss. According to recent studies, individuals on the lowest starting doses of these drugs for extended periods can still lose weight, albeit to a lesser degree compared to higher doses. After one year, those on sustained low dose tirzepatide (Mounjaro, Zepbound) lost about 5.5% of their body weight, while those on sustained low dose semaglutide (Wegovy, Zepbound) lost around 2.2%.
Despite the smaller weight loss, lower doses were linked to fewer side effects. Although the study did not confirm intentional microdosing, it suggests that staying on lower doses of GLP-1 medications could potentially provide a sustained weight loss benefit over many months. However, medical professionals note that many patients eventually require dose escalation to continue shedding weight. Common side effects of GLP-1 drugs include nausea, vomiting, and stomach issues.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
